Abstract: A method of treatment for treating, preventing, inhibiting or reducing extracellular matrix build-up in a body tissue or a bodily fluid transport vessel, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET peptide, or a conservative variant thereof, in the tissue.

Abstract: A pharmaceutically acceptable composition and method for entering a cell nucleus utilizes a cell nucleus-entering polypeptide including at least one of amino acid sequence LKKTET (SEQ ID NO: 1), amino acid sequence LKKTNT (SEQ ID NO: 2) or amino acid sequence KSKLKK (SEQ ID NO: 3), or a conservative variant thereof, linked to a physiologically active agent having at least one of therapeutic or diagnostic application in the cell nucleus.

Abstract: A composition and method utilizes a substantially purified composition including an adhesive and a polypeptide containing amino acid sequence LKKTET or a conservative variant thereof.

Abstract: A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and/or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (T?4), an isoform of T?4, an N-terminal fragment of T?4, a C-terminal fragment of T?4, T?4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, T?4ala, T?9, T?10, T?11, T?12, T?13, T?14, T?15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, ?-actinin,

Abstract: A pharmaceutically acceptable composition and method for entering a cell nucleus utilizes a cell nucleus-entering polypeptide including at least one of amino acid sequence LKKTET (SEQ ID NO:1), amino acid sequence LKKTNT (SEQ ID NO:2) or amino acid sequence KSKLKK (SEQ ID NO:3), or a conservative variant thereof, linked to a physiologically active agent having at least one of therapeutic or diagnostic application in the cell nucleus.

Abstract: A method of treatment for treating, preventing, inhibiting or reducing damage to coronary tissue includes inducing at least one of a physiological function selected from: up-regulation of or increasing ILK activity in the coronary tissue, up-regulation of or increasing Akt activity in the coronary tissue, down-regulation of or reducing cardiomyocyte cell death in the coronary tissue and hibernation of cardiomyocytes in the coronary tissue. An induction agent capable of inducing such physiological function in a subject is administered to a subject in need of such treatment.

Abstract: A method of treating or preventing tissue damage occurring subsequent to affecting an increase in blood flow through a blood vessel which is in communication with the tissue, by administering an effective amount of a composition including a tissue damage-reducing or -preventing polypeptide including at least one of Thymosin beta 4 (TB4), an isoform of TB4, an N-terminal fragment of TB4, a C-terminal fragment of TB4, TB4 sulfoxide, an LKKTET [SEQ ID NO: 1] peptide, an LKKTNT [SEQ ID NO: 2] peptide, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a conservative variant thereof having tissue damage-reducing activity. The composition is administered to the tissue before, during and/or after affecting the increase in blood flow.

Abstract: A pharmaceutical, ophthalmic or cosmetic combination or method utilizes a peptide agent include amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and further utilizes a quaternary ammonium salt, wherein the agent and the salt can be administered to a subject separately or together.

Abstract: A composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.

Abstract: A method of treatment for treating, preventing, inhibiting or reducing a biological or immunological response to a reactive chemical agent, biological agent or toxin, by tissue of a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a response-inhibiting agent including amino acid sequence LKKTET [SEQ ID NO: 1], a conservative variant thereof, or an agent that stimulates production of an LKKTET [SEQ ID NO: 1] peptide, or a conservative variant thereof, in the tissue, so as to inhibit the response.

Abstract: A method of treatment for skin, dermal or epidermal tissue utilizes a composition including an actin-binding polypeptide which may include amino acid sequence LKKTET [SEQ ID NO: 1] or a conservative variant thereof.

Abstract: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in the tissue.

Abstract: A composition including an oxidized or superoxidized methionine-containing beta thymosin peptide, isoform thereof, fragment thereof, isolated R-enantiomer thereof or isolated S-enantiomer thereof, other than racemic thymosin beta 4 sulfoxide, or a modified beta thymosin peptide, isoform or fragment thereof with an amino acid substituent substituted for at least one methionine of an amino acid sequence of a normally methionine-containing beta thymosin peptide, isoform or fragment thereof, and method for forming same.

Abstract: A composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and an ophthalmically acceptable carrier, an antimicrobially effective preservative, a tonicity agent for providing the composition with an ophthalmically acceptable tonicity, a comfort enhancing agent, at least one of an acidic or basic pH adjusting agent capable of adjusting pH of the composition to a desired ophthalmically acceptable pH level, and a buffer to substantially maintain the desired pH level.

Abstract: A composition with a polypeptide including amino acid sequence LKKTET [SEQ ID NO:1] or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.

Abstract: Inflammation or damage associated with myocardial events is treated or prevented by administration of an angiogenesis-inducing, anti-inflammatory peptide such as Thymosin &bgr;4, an isoform of Thymosin &bgr;4 or oxidized Thymosin &bgr;4.

Abstract: A composition with a polypeptide including amino acid sequence LKKTET or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.

Abstract: Blisters, sores or skin degradation associated with Epidermolysis Bullosa is treated or prevented by administration of an actin-sequestering peptide such as Thymosin &bgr;4, an isoform of Thymosin &bgr;4 or oxidized Thymosin &bgr;4.

Abstract: Eye degradation such as may be associated with dry eye syndrome is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin &bgr;4, an isoform of Tymosin &bgr;4 or oxidized Thymosin &bgr;4.

Abstract: Skin degradation associated with skin aging is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin &bgr;4, an isoform of Thymosin &bgr;4 or oxidized Thymosin &bgr;4.